Scleroderma: Overview of the Main Advanced Dressings Used in Wound Care.

IF 0.7 Q4 PHARMACOLOGY & PHARMACY
Eleonora Castellana, Maria Rachele Chiappetta
{"title":"Scleroderma: Overview of the Main Advanced Dressings Used in Wound Care.","authors":"Eleonora Castellana, Maria Rachele Chiappetta","doi":"10.1177/00185787251355443","DOIUrl":null,"url":null,"abstract":"<p><p>Scleroderma, or systemic sclerosis, is a rare and multifaceted autoimmune disorder characterized by fibrosis of connective tissues, vasculopathy, and autoimmune dysfunction, which often leads to debilitating cutaneous manifestations and digital ulcers. This disease poses significant challenges in both clinical management and patient care, particularly regarding the treatment of associated skin lesions. The pathogenesis of scleroderma involves endothelial damage, impaired vascular function, and the secretion of inflammatory mediators like endothelin-1 (ET1), leading to vasoconstriction and fibrosis. Approximately 30% to 50% of patients experience digital ulcers, which are resistant to healing and have a high risk of infection. The management of these ulcers has evolved with the introduction of advanced wound dressings, which now play a pivotal role in promoting healing and reducing complications. These dressings, such as hydrocolloids, polyurethane foams, charcoal, antimicrobial, collagen, and alginate-based products, are designed to manage various stages of wound healing-from debridement in the inflammatory phase to promoting granulation and epithelialization in later stages. The selection of an appropriate dressing is influenced by factors such as lesion stage, exudate level, presence of infection, and patient comorbidities. The hospital pharmacist is integral to this process, contributing to therapeutic selection, economic evaluation, and overall cost-effectiveness. Advanced dressings, despite their higher initial cost, offer long-term savings by reducing treatment duration and the frequency of dressing changes. The multidisciplinary approach, including the expertise of rheumatologists, pharmacists, nurses, and general practitioners, is essential for providing optimal care for scleroderma patients. This review highlights the significant progress in wound care management for scleroderma and emphasizes the importance of tailored treatments to enhance healing and patient outcomes.</p>","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787251355443"},"PeriodicalIF":0.7000,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12276201/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hospital Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/00185787251355443","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Scleroderma, or systemic sclerosis, is a rare and multifaceted autoimmune disorder characterized by fibrosis of connective tissues, vasculopathy, and autoimmune dysfunction, which often leads to debilitating cutaneous manifestations and digital ulcers. This disease poses significant challenges in both clinical management and patient care, particularly regarding the treatment of associated skin lesions. The pathogenesis of scleroderma involves endothelial damage, impaired vascular function, and the secretion of inflammatory mediators like endothelin-1 (ET1), leading to vasoconstriction and fibrosis. Approximately 30% to 50% of patients experience digital ulcers, which are resistant to healing and have a high risk of infection. The management of these ulcers has evolved with the introduction of advanced wound dressings, which now play a pivotal role in promoting healing and reducing complications. These dressings, such as hydrocolloids, polyurethane foams, charcoal, antimicrobial, collagen, and alginate-based products, are designed to manage various stages of wound healing-from debridement in the inflammatory phase to promoting granulation and epithelialization in later stages. The selection of an appropriate dressing is influenced by factors such as lesion stage, exudate level, presence of infection, and patient comorbidities. The hospital pharmacist is integral to this process, contributing to therapeutic selection, economic evaluation, and overall cost-effectiveness. Advanced dressings, despite their higher initial cost, offer long-term savings by reducing treatment duration and the frequency of dressing changes. The multidisciplinary approach, including the expertise of rheumatologists, pharmacists, nurses, and general practitioners, is essential for providing optimal care for scleroderma patients. This review highlights the significant progress in wound care management for scleroderma and emphasizes the importance of tailored treatments to enhance healing and patient outcomes.

硬皮病:用于伤口护理的主要高级敷料概述。
硬皮病,或称系统性硬化症,是一种罕见的、多方面的自身免疫性疾病,以结缔组织纤维化、血管病变和自身免疫性功能障碍为特征,常导致皮肤病变和手指溃疡。这种疾病在临床管理和患者护理方面都提出了重大挑战,特别是在相关皮肤病变的治疗方面。硬皮病的发病机制涉及内皮损伤,血管功能受损,以及内皮素-1 (ET1)等炎症介质的分泌,导致血管收缩和纤维化。大约30%至50%的患者会出现手指溃疡,这种溃疡难以愈合,感染的风险很高。随着先进的伤口敷料的引入,这些溃疡的管理已经发展,现在在促进愈合和减少并发症方面起着关键作用。这些敷料,如水胶体、聚氨酯泡沫、木炭、抗菌剂、胶原蛋白和海藻酸盐产品,被设计用于处理伤口愈合的各个阶段——从炎症期的清创到后期的促进肉芽和上皮化。选择合适的敷料受以下因素的影响:病变分期、渗出液水平、感染的存在和患者合并症。医院药剂师是这一过程中不可或缺的一部分,对治疗选择、经济评估和整体成本效益做出贡献。先进的敷料,尽管其初始成本较高,但通过减少治疗时间和更换敷料的频率,可以长期节省费用。多学科方法,包括风湿病学家、药剂师、护士和全科医生的专业知识,对于为硬皮病患者提供最佳护理至关重要。这篇综述强调了硬皮病伤口护理管理方面的重大进展,并强调了定制治疗以提高愈合和患者预后的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Hospital Pharmacy
Hospital Pharmacy PHARMACOLOGY & PHARMACY-
CiteScore
1.70
自引率
0.00%
发文量
63
期刊介绍: Hospital Pharmacy is a monthly peer-reviewed journal that is read by pharmacists and other providers practicing in the inpatient and outpatient setting within hospitals, long-term care facilities, home care, and other health-system settings The Hospital Pharmacy Assistant Editor, Michael R. Cohen, RPh, MS, DSc, FASHP, is author of a Medication Error Report Analysis and founder of The Institute for Safe Medication Practices (ISMP), a nonprofit organization that provides education about adverse drug events and their prevention.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信